

19
311716

City of Seattle

Notice of Appointment

| | | |
|---|--------------------------------------|--|
| Name: <i>Gary Stobbe</i> | | <input type="checkbox"/> Executive Appointment <input checked="" type="checkbox"/> Reappointment <input checked="" type="checkbox"/> Legislative Appointment <input type="checkbox"/> Agency Appointment <input type="checkbox"/> PDA Council <input type="checkbox"/> PDA Constituency |
| Residential Neighborhood: <i>Wallingford</i> | Zip Code: <i>98103</i> | Contact Phone No.: <i>206-598-6950</i> |
| Appointed to: <i>At-large member of the Seattle Commission for People with disAbilities</i> | | Date of Appointment: <i>July 11, 2011</i> |
| Authority (Ord., Res.): <i>S.M.C. 3.14.920</i> | | Term of Office From: <i>Confirmation</i> To: <i>April 30, 2013</i> |
| Background: <i>RE-appointment</i> Dr. Gary Stobbe is a Clinical Assistant Professor at the University of Washington Neurology and Psychiatry Departments, and Director of Adolescent and Adult Services at Seattle Children's Hospital's Autism Center. Dr. Stobbe specializes in children and adults with autism, traumatic brain injury, and multiple sclerosis. Dr. Stobbe serves on the Professional Advisory Boards of the Brain Injury Association of Washington and the Washington Chapter of the Autism Society of America. Along with his wife, Dr. Stobbe founded the Autism Spectrum Treatment and Research Center, a non-profit organization that served over two thousand individuals with autism and their families across the lifespan. Dr. Stobbe serves on the Commission's Education and Training Committee. | | |
| Authorizing Signature: <i>Bruce C. Harrell</i> | | Name and Title of Officer Making Appointments: Bruce Harrell, Council Member |



Boards & Commissions
Request for appointment and reappointment

From Felicia Yearwood

Date July 11, 2011

Following are the bios for one candidate who seeks an initial appointment and two
Notes current Commission members who request consideration for reappointment.

Seattle Commission for People with disAbilities

Saron McKee (new appointment)

Saron McKee serves as the ADA Coordinator for Seattle Housing Authority where she is responsible for ensuring accessibility, reasonable accommodations, staff training, and policy changes. Saron has a strong passion for all aspects of disability law, which has been a driving force of her education and career path. While completing access surveys across Idaho, Oregon, and Washington, she obtained her BA in Human Services and her MA in Rehabilitation Counseling, which enhanced her ability to understand and serve people with disabilities. Saron brings to the Committee her understanding of the structural and programmatic changes that have occurred over her lifetime, an extensive knowledge of applicable laws, and more than thirteen years providing services to people with disabilities.

Laura Gramer (reappointment)

Ms. Gramer serves on the board of Abused Deaf Women's Advocacy Services and works as an occupational therapist. While in Illinois, Ms. Gramer served on the Universal Access Commission, the Open Doors Organization, the Illinois Occupational Therapy Association, and the Progress Center for Independent Living. Ms. Gramer has engaged in substantial public speaking and lecturing on deafness, disability, and occupational therapy. Ms. Gramer has consistently worked to bridge the deaf and deaf-blind communities to the larger disability rights community. Until recently Ms. Gramer served as the Commission's Co-Chair.

Gary Stobbe (reappointment)

Dr. Gary Stobbe is a Clinical Assistant Professor at the University of Washington Neurology and Psychiatry Departments, and Director of Adolescent and Adult Services at Seattle Children's Hospital's Autism Center. Dr. Stobbe specializes in children and adults with autism, traumatic brain injury, and multiple sclerosis. Dr. Stobbe serves on the Professional Advisory Boards of the Brain Injury Association of Washington and the Washington Chapter of the Autism Society of America. Along with his wife, Dr. Stobbe founded the Autism Spectrum Treatment and Research Center, a non-profit organization that served over two thousand individuals with autism and their families across the lifespan. Dr. Stobbe serves on the Commission's Education and Training Committee.

Gary A. Stobbe, M.D.

University of Washington Medical Center

1959 NE Pacific St.
Box 356097
Seattle, WA 98195-6097
206-598-6950
Fax 206-598-7919
gastobbe@u.washington.edu

Seattle Children's Autism Center

P.O. Box 5371
Seattle, WA 98105
206-987-8080
Fax 206-987-8081

LICENSURE

Washington State License # 30688
DEA # - upon request

BOARDS

Board certified, Diplomate, American Board of Psychiatry and Neurology, December 1994. Recertification, August 2005.

CURRENT POSITIONS

Clinical Assistant Professor, Departments of Neurology and Psychiatry, University of Washington, 2008 – present.

Director, Adolescent and Adult Services, Seattle Children's Autism Center, Seattle Children's Hospital, 2009 – present.

Member, Western MS Center, University of Washington, 2008 – present.

PRIOR POSITIONS

Medical Director and Founder, Autism Spectrum Treatment and Research (ASTAR) Center, 2003 – 2009.

Partner, Minor & James Medical, PLLC, Department of Neurology, 2004 – 2008.

Clinical Instructor, Department of Neurology, University of Washington, 2003 – 2008.

PRIOR POSITIONS (cont.)

President, Gary Stobbe, M.D., P.S., 1998 – 2008.

Clinical Faculty, Alaska Multiple Sclerosis Center, 2003 - 2004.

Partner and Co-owner, Puget Sound Neurology, 1999 – 2003.

Clinical Associate, Edmonds Neurology Clinic, 1993 – 1998.

HOSPITAL AFFILIATIONS

**University of Washington Medical Center, Seattle, WA, Active Staff,
2008 – present.**

Seattle Children's Hospital, Seattle, WA, Active Staff, 2009 – present.

**Swedish Hospital and Medical Center, Seattle, WA, Active Staff, 2004
– 2008.**

Stevens Memorial Hospital, Edmonds, WA, Active Staff, 1993-2005.

POST M.D. TRAINING

NEUROLOGY RESIDENCY

**UCLA – West Los Angeles Veterans Administration
July '90 – June '93**

GENERAL MEDICINE INTERNSHIP

**UCLA – West Los Angeles Veterans Administration
June '89 – June '90**

MEDICAL SCHOOL

ALBANY MEDICAL COLLEGE

**Albany, New York
Doctorate of Medicine, May '89**

UNDERGRADUATE EDUCATION

UNIVERSITY OF CALIFORNIA, LOS ANGELES

Bachelor of Science, Psychobiology, June '85

ORGANIZATIONS AND OFFICES HELD

Member, Professional Advisory Committee, Brain Injury Association of Washington, 2006 – present.

Member, Professional Advisory Committee, Autism Society of Washington, 2004 – present.

Member, King County Medical Society, 2004 – present.

Member, Washington State Medical Association, 1993 – present.

Member, American Academy of Neurology, 1990 – present.

Member, American Medical Association, 1989 – present.

Member, Board of Directors, ASTAR Center, 2005 – 2009.

Member, Finance Committee, Minor & James Medical, 2007 – 2008.

Department Chair, Minor & James Medical, Department of Neurology, 2006 – 2008.

Member, Swedish Medical Center Stroke Team, 2005 – 2008.

Member, Seattle Neuroscience Institute at Swedish Medical Center, 2004 – 2008.

Member, MS Clinics at Swedish Medical Center, 2004 – 2008.

Member, Board of Directors, Minor and James Medical, 2006-2007.

President, Board of Directors, Autism Spectrum Treatment and Research (ASTAR) Center, 2002- 2004.

Member, American Heart Association, 1997 – 2003.

Member, Critical Care Committee, Stevens Memorial Hospital, 1995 – 2003.

Co-Chairman, Operation Stroke of Snohomish County, American Heart Association, 2000-2002.

ORGANIZATIONS AND OFFICES HELD (CONT.)

Board Member, American Heart Association, Snohomish County, 2000 – 2002.

Medical Director, Neurodiagnostic Services, Stevens Memorial Hospital, 1998-2001.

Member, Pharmacy and Therapeutics Committee, Stevens Memorial Hospital, 1995 – 1999.

AWARDS AND HONORS

Geraldine Dawson Award, Autism Society of Washington, 2009.

Outstanding Medical Provider, Families for Effective Autism Treatment (FEAT), Washington Chapter, 2003.

Walt Price Award, American Heart Association of Snohomish County, 2001.

Deans Honor's List, Albany Medical College, 1985 – 1986.

Athlete of the Year, TKE Fraternity, UCLA, 1985.

Regent's Scholar, UCLA, 1981 – 1985.

Psychology Honors, UCLA, 1984.

Deans Honor's List, UCLA, 1983 – 1984.

Chancellor's Scholarship, UCLA, 1981 – 1982.

RESEARCH EXPERIENCE

Co-Investigator: Evaluation of Natalizumab from the Relief of MS Associated Fatigue (ENER-G). Biogen Idec sponsored, 2007 – present.

Co-Investigator: Tysabri global observational program in safety (TYGRIS). Biogen Idec sponsored, 2007 – present.

RESEARCH EXPERIENCE (CONT.)

Hattori, N., Swan, M., Stobbe, G., et.al. Differential SPECT activation patterns associated with PASAT performance may indicate frontocerebellar functional dissociation in chronic mild traumatic brain injury. Journal of Nuclear Medicine, 2009, 50: 1054-1061.

Wundes, A., Stobbe, G., Johnson, S. et.al. Clinical experience in a large cohort of MS patients treated with natalizumab. Poster presentation, CMSC Annual Meeting, Atlanta, 2009.

Principal Investigator: A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed, parallel-group study of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder. Bristol-Myers Squibb sponsored, 2007 – 2008 (Owen, R. et.al. Pediatrics, 2009, 124 (6):1533-40.)

Principal Investigator: A phase III, randomized, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral cladribine in subjects with relapsing-remitting multiple sclerosis (RRMS), Serono sponsored, 2006 – 2008 (Giovannoni, G., N Engl J Med, 2010. DOI: 10.1056/NEJMoa0902533.)

Principal Investigator: A randomized, controlled, open-labeled, parallel group study to evaluate the effect of regularly scheduled neutralizing antibody testing on treatment patterns versus usual care in high-dose interferon treated subjects. Teva sponsored, 2007 – 2008.

Co-Investigator: Efficacy and safety of fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis. Novartis sponsored, 2006 – 2008 (Cohen, J.A., et.al. N Engl J Med, 2010. DOI: 10.1056/NEJMoa0907839.)

Co-Investigator: A randomized, multicenter, double-blind, placebo-controlled, dose-comparison study to determine the efficacy and safety of BG00012 in subjects with relapsing-remitting multiple sclerosis. Biogen Idec sponsored, 2007 – 2008.

Examining Neurologist, Autism Genetic Resource Exchange (AGRE) Study, 2004 - 2008.

RESEARCH EXPERIENCE (CONT.)

Principal Investigator: Functional imaging of cerebral reorganization in mild traumatic brain injury with cognitive fatigue. Investigator initiated (paper presentation, 31st Annual Western Regional Meeting, Society of Nuclear Medicine, October 2006; and paper presentation, Annual National Meeting, Society of Nuclear Medicine, Washington, DC, June 2007).

Principal Investigator: An fMRI study of treatment optimization recommendations comparing patients continuing treatment with glatiramer acetate 20 mg qd SC (Copaxone®) to those randomized to IFN- β -1a 30 mcg qw IM (Avonex®) in a multicenter study of patients with relapsing remitting multiple sclerosis currently on disease-modifying therapy. Biogen Idec sponsored, 2006 – 2007 (study terminated).

Principal Investigator: PediaMed Protocol 004a: Oral human Immunoglobulin in Autism: A randomized Phase II Trial to Evaluate the Safety and Efficacy of Oral Human Immunoglobulin in the Treatment of Gastrointestinal Dysfunction Associated with Autistic Disorder in Pediatric Patients from 2 – 18 Years of Age, 2004 – 2006 (Handen, B.L., et.al. J. Autism Dev. Dis., 2009, 39(5): 796-805.)

Stobbe, G., Eileen, K., Davies, J., et.al. Use of levetiracetam in children with autism spectrum disorders and electroencephalogram epileptiform abnormalities. Poster presentation, American Epilepsy Society, 2006 Annual Meeting, San Diego.

Principal Investigator, Biogen Protocol C-862: Efficacy and tolerability of Avonex Compared with Rebif (PROOF Study), study terminated 2003.

Principal Investigator, Repligen Protocol RG1068-03-00: A phase III, randomized, double-blind, placebo-controlled multiple dose study to assess the efficacy, safety and tolerability of RG1068 (human synthetic secretin) in children with autism, study completed 2004.

Principal Investigator: Serono Protocol 22982; A randomized, multicenter, parallel group, open-label study comparing the tolerability of Rebif injection with and without the use of Rebiject Mini in relapsing remitting MS patients, study completed 2002.

Investigator: Pharmacia Protocol 638-CNS-0059-013; Almotriptan Phase IV Clinical Experience Study, study completed 2002.

RESEARCH EXPERIENCE (CONT.)

Investigator: GlaxoSmithKline Protocol SUM40301; Imitrex IMPRESS Trial (Increase Migraine Painfree Response to Elevate Satisfaction), study completed 2002.

Principal Investigator: A randomized, double-blind, placebo-controlled, study to evaluate effects of YM872 on lesion volume as measured by diffusion, perfusion, and FLAIR MRI in patients with acute ischemic stroke, Yamanouchi USA sponsor, study terminated, 2001-2002.

Principal Investigator: A multicenter, stratified, randomized, double-blind, placebo-controlled study to evaluate neurologic function and disability in patients with acute ischemic stroke given tissue plasminogen activator plus YM872 or tissue plasminogen activator plus placebo, Yamanouchi USA sponsor, study terminated, 2001-2002.


Principal Investigator: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. JAMA 1999;282:2019-2026.

Principal Investigator : Intravenous tissue-type plasminogen activator for treatment of acute stroke: the standard treatment with alteplase to reverse stroke (STARS) study. JAMA 2000;283:1145-1150.

Co – Investigator: A registry of multiple sclerosis treatment and care, (MSTRAC study), 1998 – 2001.

Team Leader, VA cooperative study #265: A comparison of four treatments for generalized convulsive status epilepticus. NEJM, 1998; 339(12):792-98.

Research Fellowship, Dept. of Anatomy, Albany Medical College: A concurrent rapid onset of cytoarchitectonic differentiation throughout the cerebral neocortex in the ferret. Journal of Comparative Neurology, 1988.



July 11, 2011

Dr. Gary Stobbe
UW Medical Center
1958 Pacific St.
Seattle, WA, 98195

Dear Dr. Stobbe:

I am pleased to recommend your re-appointment as a Commissioner to the Seattle Commission for People with disAbilities. You will serve a term that ends April 30, 2013 and will be eligible for reappointment at the expiration of your term.

This appointment is subject to confirmation by the full City Council after review by the Energy, Technology, and Civil Rights Committee, which I chair. If you have any questions regarding the confirmation process, please contact Felicia Yearwood at (206) 684-4537.

You have dedicated considerable time and effort in service on the Seattle Commission for People with disAbilities and I truly appreciate your willingness to make this commitment. You bring valuable skills and experience to the Commission, and I am sure that the City benefits greatly from your participation.

Thank you for your continued service to the people of Seattle.

Sincerely,

BRUCE HARRELL,
Chair: Energy, Technology, and Civil Rights Committee
Seattle City Council

cc: Felicia Yearwood, Liaison, Seattle Office for Civil Rights
Jennifer Samuels, Committee Staff

Seattle Commission for People with disAbilities

June 27, 2011

15 Commission members: Per S.M.C. 3.14.920, confirmed by City Council, 2-years terms*

- 7 Appointed by Mayor
- 7 Appointed by City Council
- 1 Appointed by the Commission, confirmed by City Council

1 Commission member: Per S.M.C. 3.14.920 Part C, confirmed by City Council, a single 1-year term

- 1 through the Get Engaged youth leadership, Appointed by Mayor

| D | G | Name | Appointed | Term Ends | Term # | Appointed By |
|---|---|-------------------------|------------------|------------------|-----------------------|---------------------|
| 6 | F | Cory, Rebecca | 5-10-2010 | 4-30-2012 | 1 st | City Council |
| 1 | F | Foster, Vickie | 5-10-2010 | 4-30-2012 | 1 st | City Council |
| 1 | F | Lum, Mary Beth | 5-10-2010 | 4-30-2012 | 1 st | City Council |
| 6 | F | Witmer, Deborah | 5-10-2010 | 4-30-2012 | 1 st | City Council |
| 6 | F | Gramer, Laura | 5-10-2010 | 4-30-2013 | 2nd | City Council |
| 6 | M | Stobbe, Gary | 5-10-2010 | 4-30-2013 | 2nd | City Council |
| - | - | <i>Vacant (Denoyer)</i> | - | <i>4-30-2013</i> | <i>1st</i> | <i>City Council</i> |
| 6 | M | Adreon, Mark | 5-10-2010 | 4-30-2012 | 1 st | Mayor |
| 6 | F | Curtiss, Charlene | 5-10-2010 | 4-30-2012 | 1 st | Mayor |
| 2 | F | Drummond, Hope | 5-10-2010 | 4-30-2012 | 1 st | Mayor |
| 6 | F | Woody, Sara | 5-10-2010 | 4-30-2012 | 1 st | Mayor |
| 6 | M | Caple, Joshua | 5-10-2010 | 4-30-2013 | 2 nd | Mayor |
| 6 | F | Copeland, Patricia | 5-10-2010 | 4-30-2013 | 2 nd | Mayor |
| 6 | F | Sekins, Erica | 5-10-2010 | 4-30-2013 | 2 nd | Mayor |
| 5 | F | McKee, Saron | 6-27-2011 | 4-30-2013 | 1st | Commission |
| 5 | F | Mauck, Sheelarani | 1-10-2011 | 9-15-2011 | 1 st | Get Engaged |

(sorted by appointing authority, term end date, and name)

Diversity

| | | (1) | (2) | (3) | (4) | (5) | (6) | | | |
|--------------|----------|-----------|----------|----------|----------------|------------------|-------------------|-----------------|----------|-----------|
| | Men | Women | Vacant | Minority | Asian-American | African-American | Hispanic Latino/a | Native-American | Other | Caucasian |
| Mayor | 2 | 5 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 6 |
| Council | 1 | 5 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 4 |
| Commission | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1* | 0 |
| GE Program | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1** | 0 |
| Total | 3 | 12 | 1 | 5 | 2 | 1 | 0 | 0 | 2 | 10 |

*Mixed race

**Middle Eastern